Ipilimumab approved for metastatic melanoma.

@article{Traynor2011IpilimumabAF,
  title={Ipilimumab approved for metastatic melanoma.},
  author={Kate Traynor},
  journal={American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists},
  year={2011},
  volume={68 9},
  pages={768}
}
Ipilimumab approved for metastatic melanoma tion plan for health care providers, according to FDA. The recommended dosage of ipilimumab is 3 mg/kg administered intravenously over 90 minutes every three weeks for a total of four doses. The labeling provides detailed recommendations about when doses should be skipped or treatment discontinued in patients who have had an immune-related adverse event. Ipilimumab will be available in 50and 200-mg single-use vials at a concentration of 5 mg/mL in a… CONTINUE READING
Highly Cited
This paper has 84 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

85 Citations

0102030'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 85 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…